Market Overview
The chronic immune thrombocytopenia (ITP) market is anticipated to witness significant growth during 2026–2033, driven by the increasing prevalence of autoimmune disorders and rising awareness regarding early diagnosis and treatment. Growing advancements in targeted therapies, including thrombopoietin receptor agonists and monoclonal antibodies, are improving patient outcomes and expanding treatment options. Additionally, increasing healthcare expenditure and improved access to specialized care are supporting market expansion, particularly in emerging economies. Ongoing clinical research and the development of novel therapeutics are further contributing to market growth. Moreover, supportive government initiatives and patient assistance programs are enhancing treatment adoption, thereby driving the overall growth of the market globally.
Chronic Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder that occurs due to decreased platelet secretion, preventing blood clotting. An average platelet count ranges from approximately 150,000 to 400,000 per blood microliter (µL). If the count is lower than 100,000/µL of blood, the person might suffer from immune thrombocytopenia.
Chronic Immune Thrombocytopenia Market Scope
| Metrics | Details |
| CAGR | High |
| Market Size | 2023-2033 |
| Market Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For More Insights Request Free Sample
Market Dynamics: Drivers & Restraints
Increasing clinical trials
Immune thrombocytopenia is treated with immunoglobulins, steroidal drugs, and stimulating medicines, which help the body release enough platelets for blood clotting. Several drugs are under clinical trials for the treatment of primary immune thrombocytopenia in adults as well as in children. All the drugs are in phase 4 clinical trials, which are expected to be released soon in the market.
Furthermore, Sobi, Inc. is conducting phase 4 clinical trials to determine the safety and treatment satisfaction in adults With chronic (immune thrombocytopenia)ITP After switching to avatrombopag from eltrombopag or romiplostim.
Qidong Gaitianli Medicines Co., Ltd is conducting phase 4 clinical trials to evaluate the clinical efficacy and safety of Huaiqihuang granule for the treatment of children with chronic primary immune thrombocytopenia.
Side effects of steroidal drugs
Side effects of steroidal drugs in treating thrombocytopenia include severe bleeding. The side effects from corticosteroids are challenging to manage because they grow in severity as the treatment extends for a long time. The possible side effects, such as cataracts, insomnia, hypertension, changes in diabetic metabolism, etc, are also seen in people who consume steroidal drugs to treat immune thrombocytopenia.
Segment Analysis
The global chronic immune thrombocytopenia are segmented based on drug class, route of administration, distribution channel, and region.
The Platelet stimulating agents segment accounted for approximately 42.7% of the market share
Platelet-stimulating agents are expected to hold the largest mark
d TAVALISSE tab 100mg and 150mg for chronic idiopathic thrombocytopenic purpura.
Geographical Share
North America accounted for approximately 39.8% of the market share
North America is expected to hold the largest region in the market due to the prevalence of thrombocytopenia in the US population. In children, the annual incidence is estimated to be between 1 and 6.4 cases per 100,000 people.
In adults, the annual incidence is estimated to be between 1 and 6 cases per 100,000 people. However, ITP is more of a chronic disease in adults, so the prevalence is approximately 12 per 100,000 cases. The overall incidence in adults occurs in persons over 60 years old.
et share due to their efficacy in treating thrombocytopenia. Unlike corticosteroids, platelet-stimulating drugs are more efficient with fewer side effects. The launch of medications with more effectiveness and safety helps in the better treatment of thrombocytopenia in adults and children.
Market Key Players
The major global players in the chronic immune thrombocytopenia market include AbbVie Inc, Amgen Inc., Pfizer, Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Novartis International AG, Johnson & Johnson Services, Inc., Merck & Co., Inc., Bristol Myers Squibb Inc, F. Hoffmann-La Roche Ltd among others.
Recent Developments
In March 2026, Novartis AG expanded its hematology portfolio with advanced therapies targeting chronic immune thrombocytopenia. The innovation focuses on improving platelet counts and reducing bleeding risks. This supports better patient outcomes.
In February 2026, Amgen Inc. introduced next-generation thrombopoietin receptor agonists (TPO-RAs) for ITP management. The development enhances efficacy and safety profiles. This benefits long-term disease control.
In January 2026, Sanofi strengthened its autoimmune and hematology pipeline with novel biologics for ITP treatment. The focus is on targeted immune modulation. This supports precision medicine approaches.
Why Purchase the Report?
- To visualize the global chronic immune thrombocytopenia market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of chronic immune thrombocytopenia market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global chronic immune thrombocytopenia market report would provide approximately 61 tables, 59 figures, and 195 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
